A Phase Ii, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Efficacy And Safety Of Namodenoson (Cf102), An A(3) Adenosine Receptor Agonist (A(3)Ar), As A Second-Line Treatment In Patients With Child-Pugh B (Cpb) Advanced Hepatocellular Carcinoma (Hcc).

Salomon M. Stemmer,Nebojsa S. Manojlovic,Mihai Vasile Marinca, Petar Petrov,Nelly Cherciu,Doina Ganea,Tudor-Eliade Ciuleanu, Ioana Adriana Puscas,Muhammad Shaalan Beg,William T. Purcell,Adina-Emilia Croitoru,Rumyana Nedyalkova Ilieva,Sladjana Natošević,Amedeia Lavinir Nita, Dimitar Nikolaev Kalev,Zivit Harpaz,Motti Farbstein,Michael H. Silverman,Pnina Fishman,Josep M Llovet

JOURNAL OF CLINICAL ONCOLOGY（2019）

引用 9|浏览32

暂无评分

摘要

2503Background: There is no established primary treatment for patients with advanced HCC and severe liver dysfunction (Child-Pugh B class; CPB), thus this representing a clear unmet need. Namodenos...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要